Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : LMDX save search
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
Published: 2023-03-21 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.06%
H: 6.95%
C: 0.0%
year results
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
Published: 2023-02-06 (Crawled : 16:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 10.0%
H: 0.76%
C: -9.09%
fda covid solutions approval authorization molecular influenza
LumiraDx Reports Third Quarter 2022 ResultsProgress on Near-Term Growth Opportunities and Cost Savings
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.91%
H: 16.16%
C: 11.11%
growth
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
Published: 2022-10-12 (Crawled : 09:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 7.91%
H: 13.15%
C: 12.07%
care europe technology diagnostics innovation
LumiraDx Reports Second Quarter 2022 ResultsStrong Pipeline Progress and Commercialization Priorities for Newly Authorized Products
Published: 2022-08-18 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -5.33%
H: 3.52%
C: -15.49%
authorized commercialization
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
Published: 2022-08-11 (Crawled : 13:20) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.57%
H: 6.21%
C: -3.95%
conference results
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
Published: 2022-06-09 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -1.87%
H: 0.0%
C: -6.67%
covid-19 system test
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.85%
H: 11.78%
C: 11.17%
sars-cov-2
FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 8.54%
H: 3.01%
C: -7.67%
fda test molecular sars-cov-2
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 20.4%
H: 3.25%
C: -6.7%
covid test india approval covid-19
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.